Daniels, G H <br/><br/>
LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.  [electronic resource] 

 -  Diabetes, obesity & metabolism  May 2015 
 - 477-86 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.12444  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Body Mass Index<br/>Calcitonin--blood<br/>Cardiovascular Diseases--etiology<br/>Diabetes Mellitus, Type 2--blood<br/>Double-Blind Method<br/>Female<br/>Glomerular Filtration Rate<br/>Humans<br/>Hypoglycemic Agents--therapeutic use<br/>Linear Models<br/>Liraglutide--adverse effects<br/>Male<br/>Middle Aged<br/>Sex Factors